Swiss Life Asset Management’s Travere Therapeutics TVTX Stock Holding History

Swiss Life Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$336K	Buy	+5,906	New	+$262K	﹤0.01%	1191

Other funds holding TVTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Swiss Life Asset Management's TVTX Position: Q2 2026 in Review

Swiss Life Asset Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 5,906 shares worth $336K. The stake represents ﹤0.01% of the portfolio and ranks #1191 among its holdings.

186 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Swiss Life Asset Management held 5,906 shares of Travere Therapeutics worth $336K as of Q2 2026.
Travere Therapeutics was a new Swiss Life Asset Management position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1191 holding.
186 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.